Literature DB >> 12358577

Natural history of Ross River virus-induced epidemic polyarthritis.

Andrea D Mylonas1, Allison M Brown, Tracy L Carthew, Barry McGrath, David M Purdie, Nirmala Pandeya, Philip C Vecchio, Louisa G Collins, Ian D Gardner, Ferdinandus J de Looze, Elizabeth J Reymond, Andreas Suhrbier.   

Abstract

OBJECTIVE: To describe the natural history, treatment and cost of Ross River virus-induced epidemic polyarthritis (RRV disease).
DESIGN: Questionnaire-based longitudinal prospective study. PARTICIPANTS AND
SETTING: Patients in the greater Brisbane area, Queensland, diagnosed with RRV disease by their general practitioners based on clinical symptoms and paired serological tests between November 1997 and April 1999. MAIN OUTCOME MEASURES: Scores on two validated quality-of-life questionnaires (Clinical Health Assessment Questionnaire and Medical Outcomes Study Short Form 36) were obtained soon after diagnosis and one, two, three, six and 12 months thereafter. Scores were compared between patients diagnosed with RRV disease alone and those with RRV disease plus other conditions.
RESULTS: 67 patients were enrolled. Most patients with RRV disease alone had severe acute symptoms, but followed a consistent path to recovery within three to six months. Other conditions, often chronic rheumatic diseases or depression, were identified in half the cohort; their quality-of-life scores suggested stable chronic illness between six and 12 months after diagnosis. Non-steroidal anti-inflammatory drugs (NSAIDs) were taken by 58% of patients (average use, 7.6 weeks; range, 2-22 weeks). Time off work averaged 1.9 days, and direct cost to the community was estimated as 1018 Australian dollars per patient.
CONCLUSIONS: Symptom duration and frequency of long-term symptoms may have been overestimated by previous studies of RRV disease. Disease persisting six to 12 months after RRV diagnosis was largely attributable to other conditions, highlighting the need to seek other diagnoses in RRV patients with persistent symptoms.

Entities:  

Mesh:

Year:  2002        PMID: 12358577     DOI: 10.5694/j.1326-5377.2002.tb04837.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  30 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

2.  A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.

Authors:  Thomas E Morrison; Lauren Oko; Stephanie A Montgomery; Alan C Whitmore; Alina R Lotstein; Bronwyn M Gunn; Susan A Elmore; Mark T Heise
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

3.  Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis.

Authors:  Lara J Herrero; Michelle Nelson; Anon Srikiatkhachorn; Ran Gu; Surapee Anantapreecha; Günter Fingerle-Rowson; Richard Bucala; Eric Morand; Leilani L Santos; Suresh Mahalingam
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

4.  Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus.

Authors:  Kristina A Stoermer; Adam Burrack; Lauren Oko; Stephanie A Montgomery; Luke B Borst; Ronald G Gill; Thomas E Morrison
Journal:  J Immunol       Date:  2012-09-12       Impact factor: 5.422

5.  [Viral arthritis and vasculitis].

Authors:  U Sixdorf; E Märker-Hermann
Journal:  Z Rheumatol       Date:  2016-11       Impact factor: 1.372

6.  Identification and characterization of a ross river virus variant that grows persistently in macrophages, shows altered disease kinetics in a mouse model, and exhibits resistance to type I interferon.

Authors:  Brett A Lidbury; Nestor E Rulli; Cristina M Musso; Susan B Cossetto; Ali Zaid; Andreas Suhrbier; Harald S Rothenfluh; Michael S Rolph; Suresh Mahalingam
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

7.  Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis.

Authors:  Helder I Nakaya; Joy Gardner; Yee-Suan Poo; Lee Major; Bali Pulendran; Andreas Suhrbier
Journal:  Arthritis Rheum       Date:  2012-11

Review 8.  Viral arthritis.

Authors:  Michael Marks; Jonathan L Marks
Journal:  Clin Med (Lond)       Date:  2016-04       Impact factor: 2.659

Review 9.  Arthritogenic alphaviruses--an overview.

Authors:  Andreas Suhrbier; Marie-Christine Jaffar-Bandjee; Philippe Gasque
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

10.  Impact of Chikungunya virus infection on health status and quality of life: a retrospective cohort study.

Authors:  Man-Koumba Soumahoro; Patrick Gérardin; Pierre-Yves Boëlle; Joelle Perrau; Adrian Fianu; Jacques Pouchot; Denis Malvy; Antoine Flahault; François Favier; Thomas Hanslik
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.